Marcin Stajszczyk

Head of the Department

Poland

Research Interests

Explore related searches

Professors in Poland

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Marcin Stajszczyk is the Head of the Department at the Silesian Center for Rheumatology, Orthopedics and Rehabilitation in Poland. His research interests encompass the epidemiology and management of rheumatic diseases, with a focus on psoriatic arthritis, rheumatoid arthritis, and juvenile idiopathic arthritis. Recent publications highlight the incidence and prevalence of these conditions in Poland, as well as the impact of treatment accessibility and patient outcomes in the context of biosimilars. He actively contributes to national studies examining the safety and efficacy of various therapies within the rheumatologic field.

Articles (13)

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Collaborators (5)

Krzysztof Proc

Uniwersytecki Szpital Kliniczny im Jana Mikulicza-Radeckiego we Wroclawiu

POLAND

View details

Maria Maślińska

Deputy-Head of the Clinic

National Institute of Geriatrics, Rheumatology and Rehabilitation

POLAND

View details

Piotr Wiland

Wroclaw Medical University

POLAND

View details

Andrzej Fal

Wroclaw Medical University

POLAND

View details

Bogdan Batko

POLAND

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Marcin Stajszczyk

Research Interests

Explore related searches

Contact this professor

About

Articles (13)

Psoriatic arthritis incidence and prevalence trajectory in Poland—public-payer, national-level, long-term data

Comorbidity in incident rheumatoid arthritis: a nationwide case-control study with bidirectional follow-up

Epidemiology and comorbidity of juvenile idiopathic arthritis in Poland– a nationwide study

Geographical Differences in the Safety and Efficacy of Tofacitinib Versus TNFi: A Post Hoc Analysis of ORAL Surveillance

Charting the Etanercept Journey: Tracing Cost Dynamics in Poland’s Off-Patent Market from Reference Drug Rivalry to Biosimilar Monopoly

COVID-19 prophylaxis, diagnostics, and treatment in patients with rheumatic diseases. The Polish experts panel opinion

Multicenter evaluation of tofacitinib retention and safety in rheumatoid arthritis – why cardiovascular risk factors do not equate to overt risk

Access to biologics and JAK inhibitors for the treatment of rheumatic diseases in the biosimilars era in Poland: nation-level study.

Budget impact analysis and treatment availability with biosimilar TNF inhibitors in rheumatic diseases in Poland: real-world evidence using a nationwide database

Adult pneumococcal vaccination – new opportunities

The perspective of Polish patients with rheumatoid arthritis – treatment expectations, patient-reported outcomes, and digital literacy (the SENSE study)

Deep dive into achieving the therapeutic target: results from a prospective, 6-month, observational study nested in routine rheumatoid arthritis care

Tocilizumab as a first-line biologic treatment in rheumatoid arthritis patients – the impact of concomitant methotrexate treatment and Rheumatic Disease Comorbidity Index on the clinical response – results from the multicenter observational ACT-POL study

Collaborators (5)

Krzysztof Proc

Maria Maślińska

Piotr Wiland

Andrzej Fal

Bogdan Batko

Make your next move.